— First Data Presentation: Friday’s presentation marked the first public disclosure of the 6-month data from the MyopiaX-1 clinical trial…

  — Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX’s excellent safety and tolerability profile with no untoward…

– MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression – First…

– First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally –…

– Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 — Dopavision, a…

– Former Head of Novartis’ Ophthalmology Development Unit to provide significant product development expertise and industry network Berlin, Germany, November…

– Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital…

– Seventure Partners and Novartis Pharmaceuticals join as new investors – Transformative treatment for millions of children with myopia Berlin,…

Dopavision is presenting its new research findings at the ARVO conference, which is held virtually this year. The ARVO conference…

Dopavision was featured in today’s edition of the TV science program NANO by German TV station 3sat. For some time,…